ReviewFrontiers in immunology2026
Research progress on the spatiotemporal dynamics of therapy-induced senescence in remodeling the tumor microenvironment.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Natural products targeting cytokine-regulated SASP inflammation networks in Ovarian cancer: Implications on immune escape and molecular resistance.Inflammopharmacology · 2026Review
- Polyploid Giant Cancer Cells as a Senescence-Linked State in the Tumor Microenvironment.Cancers · 2026Review
- Review
- The double-edged sword of SASP in breast cancer: from tumor suppression to progression and therapy resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review systematically elaborates on the spatiotemporal dynamics and dual role of Therapy-Induced Senescence (TIS) in remodeling the Tumor Microenvironment (TME). The hallmark of TIS is the Senescence-Associated Secretory Phenotype (SASP), which drives multidimensional TME reprogramming through the secretion of various factors. These effects include the activation of Cancer-Associated Fibroblasts (CAFs), promotion of Vasculogenic Mimicry (VM), induction of metabolic reprogramming, and bidirectional regulation of the immune landscape. The article provides a focused analysis of the heterogeneous manifestations of this dual effect across different treatment stage and spatial locations, highlighting the definition of the threshold between its tumor-suppressive and tumor-promoting functions as a central current challenge. Finally, it explores future strategies involving multi-omics dynamic monitoring, artificial intelligence analysis, and spatiotemporally specific targeted interventions. In summary, this review aims to provide a theoretical foundation and translational directions for developing novel combination therapies targeting the senescent microenvironment by offering an in-depth analysis of the spatiotemporal dynamics of TIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.